ESR1 and breast carcinoma: In ER-positive/HER2-positive breast cancer cells, the co-expression of ER and HER2 activates a complex network of signaling pathways characterized by bidirectional crosstalk, ultimately promoting tumor aggressiveness and therapeutic resistance.